However, there is still a need to clarify the role of PI3K–Akt-activating mutations in melanoma after the inhibition of the MAPK pathway by focusing on the understanding of the interaction between the MAPK and PI3K–Akt pathways. The gene discussed is AKT1; the disease is melanoma.